Financial analysis of Omega Therapeutics (OMGA) compared to its rivals


Omega Therapeutics (NASDAQ: OMGA – Get Rating) is one of 259 public companies in the ‘Biologicals, Except Diagnostic’ sector, but how does it differ from its rivals? We will compare Omega Therapeutics to similar companies based on the strength of its analyst recommendations, earnings, profitability, institutional ownership, risk, valuation and dividends.

Analyst Notes

This is a summary of recent valuations and price targets for Omega Therapeutics and its rivals, as provided by MarketBeat.

Sales Ratings Hold odds Buy reviews Strong buy odds Rating
Therapeutic Omega 0 1 3 0 2.75
Competitors of Omega Therapeutics 1679 5795 11435 210 2.53

Omega Therapeutics currently has a consensus price target of $19.25, suggesting a potential upside of 808.02%. As a group, the “Biologicals, excluding diagnostics” companies have an upside potential of 114.43%. Given Omega Therapeutics’ stronger consensus rating and possible higher upside, stock analysts clearly believe Omega Therapeutics is more favorable than its rivals.

Valuation and benefits

This chart compares revenue, earnings per share (EPS), and valuation of Omega Therapeutics and its rivals.

Gross revenue Net revenue Price/earnings ratio
Therapeutic Omega $140,000.00 -$68.28 million -0.44
Competitors of Omega Therapeutics $773.46 million $147.16 million 0.05

Omega Therapeutics’ rivals have higher revenues and profits than Omega Therapeutics. Omega Therapeutics trades at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.


This table compares the net margins, return on equity and return on assets of Omega Therapeutics and its competitors.

Net margins Return on equity return on assets
Therapeutic Omega N / A -58.81% -36.39%
Competitors of Omega Therapeutics -4,587.78% -67.40% -30.70%

Institutional and insider ownership

88.9% of Omega Therapeutics shares are held by institutional investors. In comparison, 53.0% of the shares of all “Biologicals, except diagnostics” companies are held by institutional investors. 16.7% of the shares of all Biologics, Except Diagnostics companies are held by insiders of the company. Strong institutional ownership indicates that hedge funds, large money managers, and endowments believe a company is poised for long-term growth.


Omega Therapeutics beats its rivals on 6 of the 11 factors compared.

About Omega Therapeutics (Get a rating)

Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. Its OMEGA epigenomic programming platform is designed to co-opt nature’s operating system by harnessing the power of epigenetics, gene control machinery and cell differentiation. The company is developing candidate omega epigenomic controllers (OECs) to upregulate the expression of HNF4a, a master regulator of transcription as a potential way to restore liver cell function in patients with chronic liver disease; controlling the expression of genes that have been strongly linked to cell growth inhibition in patients with diabetes and other conditions to restore the regenerative capacity of the cornea; to down-regulate the expression of the CXCL1, 2, 3 and IL-8 gene cluster; controlling the expression of implicated genes in patients with idiopathic pulmonary fibrosis to halt or reverse disease progression and improve disease outcomes; to down-regulate the expression of SFRP1, a protein that inhibits hair growth; and to treat non-small cell lung cancer and small cell lung cancer. She is also developing OTX-2002 to downregulate c-Myc, an oncogene. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Get news and reviews for Omega Therapeutics Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Omega Therapeutics and related companies with’s free daily email newsletter.

Source link

Comments are closed.